TPTX Turning Point Therapeutics Inc

Price (delayed)

$75.17

Market cap

$3.73B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.57

Enterprise value

$3.43B

Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company's lead drug ...

Highlights
The net income has shrunk by 109% YoY and by 16% QoQ
The revenue has shrunk by 88% YoY and by 80% QoQ

Key stats

What are the main financial stats of TPTX
Market
Shares outstanding
49.67M
Market cap
$3.73B
Enterprise value
$3.43B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.18
Price to sales (P/S)
616.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
566.61
Earnings
Revenue
$6.05M
EBIT
-$275.49M
EBITDA
-$270.9M
Free cash flow
-$199.27M
Per share
EPS
-$5.57
Free cash flow per share
-$4.02
Book value per share
$17.96
Revenue per share
$0.12
TBVPS
$18.92
Balance sheet
Total assets
$938.79M
Total liabilities
$47.44M
Debt
$5.83M
Equity
$891.35M
Working capital
$881.87M
Liquidity
Debt to equity
0.01
Current ratio
20.35
Quick ratio
20.15
Net debt/EBITDA
1.12
Margins
EBITDA margin
-4,475.5%
Gross margin
100%
Net margin
-4,551.3%
Operating margin
-4,574.4%
Efficiency
Return on assets
-26.9%
Return on equity
-28%
Return on invested capital
-46%
Return on capital employed
-30.8%
Return on sales
-4,551.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TPTX stock price

How has the Turning Point Therapeutics stock price performed over time
Intraday
0.03%
1 week
0.95%
1 month
126.01%
1 year
-6.93%
YTD
57.59%
QTD
179.96%

Financial performance

How have Turning Point Therapeutics's revenue and profit performed over time
Revenue
$6.05M
Gross profit
$6.05M
Operating income
-$276.89M
Net income
-$275.49M
Gross margin
100%
Net margin
-4,551.3%
The net income has shrunk by 109% YoY and by 16% QoQ
TPTX's operating income has dropped by 105% year-on-year and by 16% since the previous quarter
The revenue has shrunk by 88% YoY and by 80% QoQ
TPTX's gross profit has plunged by 88% YoY and by 80% from the previous quarter

Growth

What is Turning Point Therapeutics's growth rate over time

Valuation

What is Turning Point Therapeutics stock price valuation
P/E
N/A
P/B
4.18
P/S
616.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
566.61
The EPS has plunged by 86% YoY and by 16% from the previous quarter
TPTX's P/B is 55% above its last 4 quarters average of 2.7
Turning Point Therapeutics's equity has decreased by 19% YoY and by 7% from the previous quarter
The revenue has shrunk by 88% YoY and by 80% QoQ

Efficiency

How efficient is Turning Point Therapeutics business performance
Turning Point Therapeutics's return on equity has shrunk by 92% YoY and by 22% QoQ
Turning Point Therapeutics's ROA has plunged by 89% YoY and by 22% from the previous quarter
The ROIC has plunged by 60% YoY and by 19% from the previous quarter

Dividends

What is TPTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TPTX.

Financial health

How did Turning Point Therapeutics financials performed over time
The total liabilities has soared by 80% YoY but it fell by 3.3% QoQ
The current ratio has dropped by 56% year-on-year and by 3.5% since the previous quarter
The debt is 99% less than the equity
The debt has soared by 67% YoY and by 4.6% from the previous quarter
Turning Point Therapeutics's equity has decreased by 19% YoY and by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.